查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1866592

頭孢曲松鈉：全球市場佔有率和排名、總收入和需求預測（2025-2031 年）

Ceftriaxone Sodium - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
出版日期: | 出版商: QYResearch | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2024 年全球頭孢曲松鈉市場規模預計為 2.5 億美元，預計到 2031 年將萎縮至 2.07 億美元，2025 年至 2031 年的複合年成長率為 -2.7%。

本報告對近期關稅調整和國際戰略反制措施對頭孢曲松鈉跨境產業佈局、資本配置模式、區域經濟相互依存關係和供應鏈重組的影響進行了全面評估。

頭孢曲松鈉是一種頻譜第三代頭孢菌素類抗生素，其殺菌作用機轉是透過抑制細菌細胞壁合成。它用於治療呼吸道感染疾病、泌尿系統感染疾病、皮膚和軟組織感染疾病、敗血症和腦膜炎。由於其半衰期長、作用持久、耐受性好，且可靜脈注射或肌肉注射，因此在臨床上已廣泛應用。近年來，隨著抗生素抗藥性的增加和全球感染疾病負擔的持續加重，醫院、社區衛生機構和緊急感染控制領域對頭孢曲松鈉的需求穩步成長。生產商正在最佳化生產流程並整合原料，以提高效率和產品品質的穩定性。本報告分析了頭孢曲松鈉活性原料藥。預計2024年全球產量約2,766噸，平均市場價格約為每公斤94美元。

全球感染疾病負擔持續加重，尤其是在開發中國家和人口老化地區，這推動了抗生素需求的穩定成長，並為頭孢曲松鈉市場提供了強勁的驅動力。世界各國政府正在實施相關政策，以促進抗生素的合理使用、擴大醫療覆蓋範圍並更新臨床指南，鼓勵醫院購買高品質的抗生素。根據主要製藥企業的年度報告，他們持續投資於原料整合、產能擴張和新製劑研發，以確保供應穩定和產品多樣化。一份券商報告指出，抗菌素抗藥性應對措施、社區感染控制和標準化臨床應用的發展趨勢將進一步推動頭孢曲松鈉在醫院和基層醫療機構的市場滲透。

頭孢曲松鈉產業面臨許多挑戰，例如原料價格波動、生產流程複雜以及嚴格的國際品質標準。年度報告顯示，部分關鍵原料依賴進口，供應鏈波動可能影響生產穩定性。抗生素抗藥性問題、監管力度加大、集中採購、價格上限等因素可能對中價格分佈產品的利潤率構成壓力。此外，拓展跨境市場需要企業遵守註冊核准、市場進入以及應對監管差異，這增加了企業的營運風險。

來自醫院、社區健康組織和公共衛生部門的下游需求呈現穩定成長，並伴隨著結構最佳化。臨床醫師傾向於選擇保存期限長、給藥方案靈活且可靜脈注射或肌肉注射的製劑，以便治療多種感染疾病類型和應對緊急情況。據仲介報告顯示，推廣抗菌藥物管理、醫院用藥標準化以及引入數位化藥物管理系統有望提高頭孢曲松鈉的臨床依從性和庫存效率，而高附加價值製劑和新型緩釋性產品可能成為未來市場差異化的關鍵。

本報告旨在按地區/國家、類型和應用對全球頭孢曲松鈉市場進行全面分析，重點關注總銷售量、收入、價格、市場佔有率和主要企業的排名。

本報告以銷售量（噸）和收入（百萬美元）為單位，提供頭孢曲松鈉市場規模、估計值和預測，基準年為2024年，並包含2020年至2031年的歷史數據和預測數據。報告採用定量和定性分析相結合的方法，幫助讀者制定頭孢曲松鈉的業務和成長策略，評估市場競爭，分析自身在當前市場中的地位，並做出明智的商業決策。

市場區隔

公司

  • Shandong Ruiying
  • Qilu Antibiotics
  • Nectar Lifesciences
  • Kelun
  • United Laboratories
  • Aurobindo Pharma
  • Orchid Pharma
  • Medya Pharma
  • REYOUNG
  • LKPC
  • ACS Dobfar
  • NCPC
  • Dawnrays
  • Kopran

按類型分類的細分市場

  • ChP
  • USP
  • EP

應用領域

  • 單次注射
  • 複合注射

按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 韓國
    • 東南亞
    • 印度
    • 澳洲
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 荷蘭
    • 北歐國家
    • 其他歐洲
  • 拉丁美洲
    • 墨西哥
    • 巴西
    • 其他拉丁美洲
  • 中東和非洲
    • 土耳其
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區

The global market for Ceftriaxone Sodium was estimated to be worth US$ 250 million in 2024 and is forecast to a readjusted size of US$ 207 million by 2031 with a CAGR of -2.7% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Ceftriaxone Sodium cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Ceftriaxone Sodium is a broad-spectrum third-generation cephalosporin antibiotic that exerts bactericidal effects by inhibiting bacterial cell wall synthesis. It is indicated for the treatment of respiratory tract infections, urinary and reproductive system infections, skin and soft tissue infections, sepsis, and meningitis. The drug features a long half-life, sustained action, good tolerability, and can be administered via intravenous or intramuscular injection, making it widely applicable in clinical practice. In recent years, with increasing antibiotic resistance and the ongoing global burden of infectious diseases, the demand for ceftriaxone sodium in hospitals, community healthcare settings, and emergency infection control has grown steadily. Manufacturers have also optimized production processes and integrated raw materials to improve efficiency and product quality stability.In this report, we study the Ceftriaxone Sodium API.In 2024, global Ceftriaxone Sodium production reached approximately 2766 mt, with an average global market price of around US$ 94 per kg.

The global burden of infectious diseases continues to rise, particularly in developing countries and regions with aging populations, driving steady growth in demand for antibiotics and providing a strong growth impetus for the ceftriaxone sodium market. Governments are promoting policies for rational antibiotic use, insurance coverage, and updated clinical guidelines, encouraging hospitals to procure high-quality antibiotics. Annual reports indicate that leading pharmaceutical manufacturers continue to invest in raw material integration, capacity expansion, and development of new formulations to ensure supply stability and product diversity. Brokerage reports highlight that antimicrobial resistance control, community infection management, and standardized clinical usage trends will further increase market penetration of ceftriaxone sodium in hospitals and primary care facilities.

The ceftriaxone sodium industry faces challenges such as raw material price volatility, complex production processes, and strict international quality standards. Annual reports reveal that key raw materials are partially imported, and supply chain fluctuations may impact production stability. Antibiotic resistance issues, strengthened regulatory oversight, and centralized procurement or price caps may pressure mid- to low-end product margins. Cross-border market expansion must also navigate registration approvals, market access, and regulatory differences, increasing operational risks for enterprises.

Downstream demand from hospitals, community healthcare institutions, and public health departments shows stable growth with structural optimization. Clinicians prefer formulations suitable for long-term storage, flexible dosing regimens, and both intravenous and intramuscular administration to address different infection types and emergency scenarios. Brokerage reports indicate that with the promotion of rational antibiotic use, hospital medication standardization, and digital drug management systems, ceftriaxone sodium is expected to achieve higher clinical adherence and inventory efficiency, while high-end formulations and novel extended-release products may become key points of market differentiation in the future.

This report aims to provide a comprehensive presentation of the global market for Ceftriaxone Sodium, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Ceftriaxone Sodium by region & country, by Type, and by Application.

The Ceftriaxone Sodium market size, estimations, and forecasts are provided in terms of sales volume (MT) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ceftriaxone Sodium.

Market Segmentation

By Company

  • Shandong Ruiying
  • Qilu Antibiotics
  • Nectar Lifesciences
  • Kelun
  • United Laboratories
  • Aurobindo Pharma
  • Orchid Pharma
  • Medya Pharma
  • REYOUNG
  • LKPC
  • ACS Dobfar
  • NCPC
  • Dawnrays
  • Kopran

Segment by Type

  • ChP
  • USP
  • EP

Segment by Application

  • Single Injection
  • Compound Injection

By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Netherlands
    • Nordic Countries
    • Rest of Europe
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Ceftriaxone Sodium manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Ceftriaxone Sodium in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Ceftriaxone Sodium in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

  • 1.1 Ceftriaxone Sodium Product Introduction
  • 1.2 Global Ceftriaxone Sodium Market Size Forecast
    • 1.2.1 Global Ceftriaxone Sodium Sales Value (2020-2031)
    • 1.2.2 Global Ceftriaxone Sodium Sales Volume (2020-2031)
    • 1.2.3 Global Ceftriaxone Sodium Sales Price (2020-2031)
  • 1.3 Ceftriaxone Sodium Market Trends & Drivers
    • 1.3.1 Ceftriaxone Sodium Industry Trends
    • 1.3.2 Ceftriaxone Sodium Market Drivers & Opportunity
    • 1.3.3 Ceftriaxone Sodium Market Challenges
    • 1.3.4 Ceftriaxone Sodium Market Restraints
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Competitive Analysis by Company

  • 2.1 Global Ceftriaxone Sodium Players Revenue Ranking (2024)
  • 2.2 Global Ceftriaxone Sodium Revenue by Company (2020-2025)
  • 2.3 Global Ceftriaxone Sodium Players Sales Volume Ranking (2024)
  • 2.4 Global Ceftriaxone Sodium Sales Volume by Company Players (2020-2025)
  • 2.5 Global Ceftriaxone Sodium Average Price by Company (2020-2025)
  • 2.6 Key Manufacturers Ceftriaxone Sodium Manufacturing Base and Headquarters
  • 2.7 Key Manufacturers Ceftriaxone Sodium Product Offered
  • 2.8 Key Manufacturers Time to Begin Mass Production of Ceftriaxone Sodium
  • 2.9 Ceftriaxone Sodium Market Competitive Analysis
    • 2.9.1 Ceftriaxone Sodium Market Concentration Rate (2020-2025)
    • 2.9.2 Global 5 and 10 Largest Manufacturers by Ceftriaxone Sodium Revenue in 2024
    • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ceftriaxone Sodium as of 2024)
  • 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

  • 3.1 Introduction by Type
    • 3.1.1 ChP
    • 3.1.2 USP
    • 3.1.3 EP
  • 3.2 Global Ceftriaxone Sodium Sales Value by Type
    • 3.2.1 Global Ceftriaxone Sodium Sales Value by Type (2020 VS 2024 VS 2031)
    • 3.2.2 Global Ceftriaxone Sodium Sales Value, by Type (2020-2031)
    • 3.2.3 Global Ceftriaxone Sodium Sales Value, by Type (%) (2020-2031)
  • 3.3 Global Ceftriaxone Sodium Sales Volume by Type
    • 3.3.1 Global Ceftriaxone Sodium Sales Volume by Type (2020 VS 2024 VS 2031)
    • 3.3.2 Global Ceftriaxone Sodium Sales Volume, by Type (2020-2031)
    • 3.3.3 Global Ceftriaxone Sodium Sales Volume, by Type (%) (2020-2031)
  • 3.4 Global Ceftriaxone Sodium Average Price by Type (2020-2031)

4 Segmentation by Application

  • 4.1 Introduction by Application
    • 4.1.1 Single Injection
    • 4.1.2 Compound Injection
  • 4.2 Global Ceftriaxone Sodium Sales Value by Application
    • 4.2.1 Global Ceftriaxone Sodium Sales Value by Application (2020 VS 2024 VS 2031)
    • 4.2.2 Global Ceftriaxone Sodium Sales Value, by Application (2020-2031)
    • 4.2.3 Global Ceftriaxone Sodium Sales Value, by Application (%) (2020-2031)
  • 4.3 Global Ceftriaxone Sodium Sales Volume by Application
    • 4.3.1 Global Ceftriaxone Sodium Sales Volume by Application (2020 VS 2024 VS 2031)
    • 4.3.2 Global Ceftriaxone Sodium Sales Volume, by Application (2020-2031)
    • 4.3.3 Global Ceftriaxone Sodium Sales Volume, by Application (%) (2020-2031)
  • 4.4 Global Ceftriaxone Sodium Average Price by Application (2020-2031)

5 Segmentation by Region

  • 5.1 Global Ceftriaxone Sodium Sales Value by Region
    • 5.1.1 Global Ceftriaxone Sodium Sales Value by Region: 2020 VS 2024 VS 2031
    • 5.1.2 Global Ceftriaxone Sodium Sales Value by Region (2020-2025)
    • 5.1.3 Global Ceftriaxone Sodium Sales Value by Region (2026-2031)
    • 5.1.4 Global Ceftriaxone Sodium Sales Value by Region (%), (2020-2031)
  • 5.2 Global Ceftriaxone Sodium Sales Volume by Region
    • 5.2.1 Global Ceftriaxone Sodium Sales Volume by Region: 2020 VS 2024 VS 2031
    • 5.2.2 Global Ceftriaxone Sodium Sales Volume by Region (2020-2025)
    • 5.2.3 Global Ceftriaxone Sodium Sales Volume by Region (2026-2031)
    • 5.2.4 Global Ceftriaxone Sodium Sales Volume by Region (%), (2020-2031)
  • 5.3 Global Ceftriaxone Sodium Average Price by Region (2020-2031)
  • 5.4 North America
    • 5.4.1 North America Ceftriaxone Sodium Sales Value, 2020-2031
    • 5.4.2 North America Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
  • 5.5 Europe
    • 5.5.1 Europe Ceftriaxone Sodium Sales Value, 2020-2031
    • 5.5.2 Europe Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
  • 5.6 Asia Pacific
    • 5.6.1 Asia Pacific Ceftriaxone Sodium Sales Value, 2020-2031
    • 5.6.2 Asia Pacific Ceftriaxone Sodium Sales Value by Region (%), 2024 VS 2031
  • 5.7 South America
    • 5.7.1 South America Ceftriaxone Sodium Sales Value, 2020-2031
    • 5.7.2 South America Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
  • 5.8 Middle East & Africa
    • 5.8.1 Middle East & Africa Ceftriaxone Sodium Sales Value, 2020-2031
    • 5.8.2 Middle East & Africa Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

  • 6.1 Key Countries/Regions Ceftriaxone Sodium Sales Value Growth Trends, 2020 VS 2024 VS 2031
  • 6.2 Key Countries/Regions Ceftriaxone Sodium Sales Value and Sales Volume
    • 6.2.1 Key Countries/Regions Ceftriaxone Sodium Sales Value, 2020-2031
    • 6.2.2 Key Countries/Regions Ceftriaxone Sodium Sales Volume, 2020-2031
  • 6.3 United States
    • 6.3.1 United States Ceftriaxone Sodium Sales Value, 2020-2031
    • 6.3.2 United States Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
    • 6.3.3 United States Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
  • 6.4 Europe
    • 6.4.1 Europe Ceftriaxone Sodium Sales Value, 2020-2031
    • 6.4.2 Europe Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
    • 6.4.3 Europe Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
  • 6.5 China
    • 6.5.1 China Ceftriaxone Sodium Sales Value, 2020-2031
    • 6.5.2 China Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
    • 6.5.3 China Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
  • 6.6 Japan
    • 6.6.1 Japan Ceftriaxone Sodium Sales Value, 2020-2031
    • 6.6.2 Japan Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
    • 6.6.3 Japan Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
  • 6.7 South Korea
    • 6.7.1 South Korea Ceftriaxone Sodium Sales Value, 2020-2031
    • 6.7.2 South Korea Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
    • 6.7.3 South Korea Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
  • 6.8 Southeast Asia
    • 6.8.1 Southeast Asia Ceftriaxone Sodium Sales Value, 2020-2031
    • 6.8.2 Southeast Asia Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
    • 6.8.3 Southeast Asia Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
  • 6.9 India
    • 6.9.1 India Ceftriaxone Sodium Sales Value, 2020-2031
    • 6.9.2 India Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
    • 6.9.3 India Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031

7 Company Profiles

  • 7.1 Shandong Ruiying
    • 7.1.1 Shandong Ruiying Company Information
    • 7.1.2 Shandong Ruiying Introduction and Business Overview
    • 7.1.3 Shandong Ruiying Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.1.4 Shandong Ruiying Ceftriaxone Sodium Product Offerings
    • 7.1.5 Shandong Ruiying Recent Development
  • 7.2 Qilu Antibiotics
    • 7.2.1 Qilu Antibiotics Company Information
    • 7.2.2 Qilu Antibiotics Introduction and Business Overview
    • 7.2.3 Qilu Antibiotics Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.2.4 Qilu Antibiotics Ceftriaxone Sodium Product Offerings
    • 7.2.5 Qilu Antibiotics Recent Development
  • 7.3 Nectar Lifesciences
    • 7.3.1 Nectar Lifesciences Company Information
    • 7.3.2 Nectar Lifesciences Introduction and Business Overview
    • 7.3.3 Nectar Lifesciences Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.3.4 Nectar Lifesciences Ceftriaxone Sodium Product Offerings
    • 7.3.5 Nectar Lifesciences Recent Development
  • 7.4 Kelun
    • 7.4.1 Kelun Company Information
    • 7.4.2 Kelun Introduction and Business Overview
    • 7.4.3 Kelun Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.4.4 Kelun Ceftriaxone Sodium Product Offerings
    • 7.4.5 Kelun Recent Development
  • 7.5 United Laboratories
    • 7.5.1 United Laboratories Company Information
    • 7.5.2 United Laboratories Introduction and Business Overview
    • 7.5.3 United Laboratories Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.5.4 United Laboratories Ceftriaxone Sodium Product Offerings
    • 7.5.5 United Laboratories Recent Development
  • 7.6 Aurobindo Pharma
    • 7.6.1 Aurobindo Pharma Company Information
    • 7.6.2 Aurobindo Pharma Introduction and Business Overview
    • 7.6.3 Aurobindo Pharma Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.6.4 Aurobindo Pharma Ceftriaxone Sodium Product Offerings
    • 7.6.5 Aurobindo Pharma Recent Development
  • 7.7 Orchid Pharma
    • 7.7.1 Orchid Pharma Company Information
    • 7.7.2 Orchid Pharma Introduction and Business Overview
    • 7.7.3 Orchid Pharma Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.7.4 Orchid Pharma Ceftriaxone Sodium Product Offerings
    • 7.7.5 Orchid Pharma Recent Development
  • 7.8 Medya Pharma
    • 7.8.1 Medya Pharma Company Information
    • 7.8.2 Medya Pharma Introduction and Business Overview
    • 7.8.3 Medya Pharma Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.8.4 Medya Pharma Ceftriaxone Sodium Product Offerings
    • 7.8.5 Medya Pharma Recent Development
  • 7.9 REYOUNG
    • 7.9.1 REYOUNG Company Information
    • 7.9.2 REYOUNG Introduction and Business Overview
    • 7.9.3 REYOUNG Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.9.4 REYOUNG Ceftriaxone Sodium Product Offerings
    • 7.9.5 REYOUNG Recent Development
  • 7.10 LKPC
    • 7.10.1 LKPC Company Information
    • 7.10.2 LKPC Introduction and Business Overview
    • 7.10.3 LKPC Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.10.4 LKPC Ceftriaxone Sodium Product Offerings
    • 7.10.5 LKPC Recent Development
  • 7.11 ACS Dobfar
    • 7.11.1 ACS Dobfar Company Information
    • 7.11.2 ACS Dobfar Introduction and Business Overview
    • 7.11.3 ACS Dobfar Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.11.4 ACS Dobfar Ceftriaxone Sodium Product Offerings
    • 7.11.5 ACS Dobfar Recent Development
  • 7.12 NCPC
    • 7.12.1 NCPC Company Information
    • 7.12.2 NCPC Introduction and Business Overview
    • 7.12.3 NCPC Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.12.4 NCPC Ceftriaxone Sodium Product Offerings
    • 7.12.5 NCPC Recent Development
  • 7.13 Dawnrays
    • 7.13.1 Dawnrays Company Information
    • 7.13.2 Dawnrays Introduction and Business Overview
    • 7.13.3 Dawnrays Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.13.4 Dawnrays Ceftriaxone Sodium Product Offerings
    • 7.13.5 Dawnrays Recent Development
  • 7.14 Kopran
    • 7.14.1 Kopran Company Information
    • 7.14.2 Kopran Introduction and Business Overview
    • 7.14.3 Kopran Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
    • 7.14.4 Kopran Ceftriaxone Sodium Product Offerings
    • 7.14.5 Kopran Recent Development

8 Industry Chain Analysis

  • 8.1 Ceftriaxone Sodium Industrial Chain
  • 8.2 Ceftriaxone Sodium Upstream Analysis
    • 8.2.1 Key Raw Materials
    • 8.2.2 Raw Materials Key Suppliers
    • 8.2.3 Manufacturing Cost Structure
  • 8.3 Midstream Analysis
  • 8.4 Downstream Analysis (Customers Analysis)
  • 8.5 Sales Model and Sales Channels
    • 8.5.1 Ceftriaxone Sodium Sales Model
    • 8.5.2 Sales Channel
    • 8.5.3 Ceftriaxone Sodium Distributors

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer

List of Tables

  • Table 1. Ceftriaxone Sodium Market Trends
  • Table 2. Ceftriaxone Sodium Market Drivers & Opportunity
  • Table 3. Ceftriaxone Sodium Market Challenges
  • Table 4. Ceftriaxone Sodium Market Restraints
  • Table 5. Global Ceftriaxone Sodium Revenue by Company (2020-2025) & (US$ Million)
  • Table 6. Global Ceftriaxone Sodium Revenue Market Share by Company (2020-2025)
  • Table 7. Global Ceftriaxone Sodium Sales Volume by Company (2020-2025) & (MT)
  • Table 8. Global Ceftriaxone Sodium Sales Volume Market Share by Company (2020-2025)
  • Table 9. Global Market Ceftriaxone Sodium Price by Company (2020-2025) & (USD/Kg)
  • Table 10. Key Manufacturers Ceftriaxone Sodium Manufacturing Base and Headquarters
  • Table 11. Key Manufacturers Ceftriaxone Sodium Product Type
  • Table 12. Key Manufacturers Time to Begin Mass Production of Ceftriaxone Sodium
  • Table 13. Global Ceftriaxone Sodium Manufacturers Market Concentration Ratio (CR5 and HHI)
  • Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ceftriaxone Sodium as of 2024)
  • Table 15. Mergers & Acquisitions, Expansion Plans
  • Table 16. Global Ceftriaxone Sodium Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 17. Global Ceftriaxone Sodium Sales Value by Type (2020-2025) & (US$ Million)
  • Table 18. Global Ceftriaxone Sodium Sales Value by Type (2026-2031) & (US$ Million)
  • Table 19. Global Ceftriaxone Sodium Sales Market Share in Value by Type (2020-2025)
  • Table 20. Global Ceftriaxone Sodium Sales Market Share in Value by Type (2026-2031)
  • Table 21. Global Ceftriaxone Sodium Sales Volume by Type: 2020 VS 2024 VS 2031 (MT)
  • Table 22. Global Ceftriaxone Sodium Sales Volume by Type (2020-2025) & (MT)
  • Table 23. Global Ceftriaxone Sodium Sales Volume by Type (2026-2031) & (MT)
  • Table 24. Global Ceftriaxone Sodium Sales Market Share in Volume by Type (2020-2025)
  • Table 25. Global Ceftriaxone Sodium Sales Market Share in Volume by Type (2026-2031)
  • Table 26. Global Ceftriaxone Sodium Price by Type (2020-2025) & (USD/Kg)
  • Table 27. Global Ceftriaxone Sodium Price by Type (2026-2031) & (USD/Kg)
  • Table 28. Global Ceftriaxone Sodium Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
  • Table 29. Global Ceftriaxone Sodium Sales Value by Application (2020-2025) & (US$ Million)
  • Table 30. Global Ceftriaxone Sodium Sales Value by Application (2026-2031) & (US$ Million)
  • Table 31. Global Ceftriaxone Sodium Sales Market Share in Value by Application (2020-2025)
  • Table 32. Global Ceftriaxone Sodium Sales Market Share in Value by Application (2026-2031)
  • Table 33. Global Ceftriaxone Sodium Sales Volume by Application: 2020 VS 2024 VS 2031 (MT)
  • Table 34. Global Ceftriaxone Sodium Sales Volume by Application (2020-2025) & (MT)
  • Table 35. Global Ceftriaxone Sodium Sales Volume by Application (2026-2031) & (MT)
  • Table 36. Global Ceftriaxone Sodium Sales Market Share in Volume by Application (2020-2025)
  • Table 37. Global Ceftriaxone Sodium Sales Market Share in Volume by Application (2026-2031)
  • Table 38. Global Ceftriaxone Sodium Price by Application (2020-2025) & (USD/Kg)
  • Table 39. Global Ceftriaxone Sodium Price by Application (2026-2031) & (USD/Kg)
  • Table 40. Global Ceftriaxone Sodium Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
  • Table 41. Global Ceftriaxone Sodium Sales Value by Region (2020-2025) & (US$ Million)
  • Table 42. Global Ceftriaxone Sodium Sales Value by Region (2026-2031) & (US$ Million)
  • Table 43. Global Ceftriaxone Sodium Sales Value by Region (2020-2025) & (%)
  • Table 44. Global Ceftriaxone Sodium Sales Value by Region (2026-2031) & (%)
  • Table 45. Global Ceftriaxone Sodium Sales Volume by Region (MT): 2020 VS 2024 VS 2031
  • Table 46. Global Ceftriaxone Sodium Sales Volume by Region (2020-2025) & (MT)
  • Table 47. Global Ceftriaxone Sodium Sales Volume by Region (2026-2031) & (MT)
  • Table 48. Global Ceftriaxone Sodium Sales Volume by Region (2020-2025) & (%)
  • Table 49. Global Ceftriaxone Sodium Sales Volume by Region (2026-2031) & (%)
  • Table 50. Global Ceftriaxone Sodium Average Price by Region (2020-2025) & (USD/Kg)
  • Table 51. Global Ceftriaxone Sodium Average Price by Region (2026-2031) & (USD/Kg)
  • Table 52. Key Countries/Regions Ceftriaxone Sodium Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
  • Table 53. Key Countries/Regions Ceftriaxone Sodium Sales Value, (2020-2025) & (US$ Million)
  • Table 54. Key Countries/Regions Ceftriaxone Sodium Sales Value, (2026-2031) & (US$ Million)
  • Table 55. Key Countries/Regions Ceftriaxone Sodium Sales Volume, (2020-2025) & (MT)
  • Table 56. Key Countries/Regions Ceftriaxone Sodium Sales Volume, (2026-2031) & (MT)
  • Table 57. Shandong Ruiying Company Information
  • Table 58. Shandong Ruiying Introduction and Business Overview
  • Table 59. Shandong Ruiying Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 60. Shandong Ruiying Ceftriaxone Sodium Product Offerings
  • Table 61. Shandong Ruiying Recent Development
  • Table 62. Qilu Antibiotics Company Information
  • Table 63. Qilu Antibiotics Introduction and Business Overview
  • Table 64. Qilu Antibiotics Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 65. Qilu Antibiotics Ceftriaxone Sodium Product Offerings
  • Table 66. Qilu Antibiotics Recent Development
  • Table 67. Nectar Lifesciences Company Information
  • Table 68. Nectar Lifesciences Introduction and Business Overview
  • Table 69. Nectar Lifesciences Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 70. Nectar Lifesciences Ceftriaxone Sodium Product Offerings
  • Table 71. Nectar Lifesciences Recent Development
  • Table 72. Kelun Company Information
  • Table 73. Kelun Introduction and Business Overview
  • Table 74. Kelun Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 75. Kelun Ceftriaxone Sodium Product Offerings
  • Table 76. Kelun Recent Development
  • Table 77. United Laboratories Company Information
  • Table 78. United Laboratories Introduction and Business Overview
  • Table 79. United Laboratories Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 80. United Laboratories Ceftriaxone Sodium Product Offerings
  • Table 81. United Laboratories Recent Development
  • Table 82. Aurobindo Pharma Company Information
  • Table 83. Aurobindo Pharma Introduction and Business Overview
  • Table 84. Aurobindo Pharma Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 85. Aurobindo Pharma Ceftriaxone Sodium Product Offerings
  • Table 86. Aurobindo Pharma Recent Development
  • Table 87. Orchid Pharma Company Information
  • Table 88. Orchid Pharma Introduction and Business Overview
  • Table 89. Orchid Pharma Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 90. Orchid Pharma Ceftriaxone Sodium Product Offerings
  • Table 91. Orchid Pharma Recent Development
  • Table 92. Medya Pharma Company Information
  • Table 93. Medya Pharma Introduction and Business Overview
  • Table 94. Medya Pharma Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 95. Medya Pharma Ceftriaxone Sodium Product Offerings
  • Table 96. Medya Pharma Recent Development
  • Table 97. REYOUNG Company Information
  • Table 98. REYOUNG Introduction and Business Overview
  • Table 99. REYOUNG Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 100. REYOUNG Ceftriaxone Sodium Product Offerings
  • Table 101. REYOUNG Recent Development
  • Table 102. LKPC Company Information
  • Table 103. LKPC Introduction and Business Overview
  • Table 104. LKPC Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 105. LKPC Ceftriaxone Sodium Product Offerings
  • Table 106. LKPC Recent Development
  • Table 107. ACS Dobfar Company Information
  • Table 108. ACS Dobfar Introduction and Business Overview
  • Table 109. ACS Dobfar Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 110. ACS Dobfar Ceftriaxone Sodium Product Offerings
  • Table 111. ACS Dobfar Recent Development
  • Table 112. NCPC Company Information
  • Table 113. NCPC Introduction and Business Overview
  • Table 114. NCPC Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 115. NCPC Ceftriaxone Sodium Product Offerings
  • Table 116. NCPC Recent Development
  • Table 117. Dawnrays Company Information
  • Table 118. Dawnrays Introduction and Business Overview
  • Table 119. Dawnrays Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 120. Dawnrays Ceftriaxone Sodium Product Offerings
  • Table 121. Dawnrays Recent Development
  • Table 122. Kopran Company Information
  • Table 123. Kopran Introduction and Business Overview
  • Table 124. Kopran Ceftriaxone Sodium Sales (MT), Revenue (US$ Million), Price (USD/Kg) and Gross Margin (2020-2025)
  • Table 125. Kopran Ceftriaxone Sodium Product Offerings
  • Table 126. Kopran Recent Development
  • Table 127. Key Raw Materials Lists
  • Table 128. Raw Materials Key Suppliers Lists
  • Table 129. Ceftriaxone Sodium Downstream Customers
  • Table 130. Ceftriaxone Sodium Distributors List
  • Table 131. Research Programs/Design for This Report
  • Table 132. Key Data Information from Secondary Sources
  • Table 133. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Ceftriaxone Sodium Product Picture
  • Figure 2. Global Ceftriaxone Sodium Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
  • Figure 3. Global Ceftriaxone Sodium Sales Value (2020-2031) & (US$ Million)
  • Figure 4. Global Ceftriaxone Sodium Sales Volume (2020-2031) & (MT)
  • Figure 5. Global Ceftriaxone Sodium Sales Price (2020-2031) & (USD/Kg)
  • Figure 6. Ceftriaxone Sodium Report Years Considered
  • Figure 7. Global Ceftriaxone Sodium Players Revenue Ranking (2024) & (US$ Million)
  • Figure 8. Global Ceftriaxone Sodium Players Sales Volume Ranking (2024) & (MT)
  • Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Ceftriaxone Sodium Revenue in 2024
  • Figure 10. Ceftriaxone Sodium Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
  • Figure 11. ChP Picture
  • Figure 12. USP Picture
  • Figure 13. EP Picture
  • Figure 14. Global Ceftriaxone Sodium Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 15. Global Ceftriaxone Sodium Sales Value Market Share by Type, 2024 & 2031
  • Figure 16. Global Ceftriaxone Sodium Sales Volume by Type (2020 VS 2024 VS 2031) & (MT)
  • Figure 17. Global Ceftriaxone Sodium Sales Volume Market Share by Type, 2024 & 2031
  • Figure 18. Global Ceftriaxone Sodium Price by Type (2020-2031) & (USD/Kg)
  • Figure 19. Product Picture of Single Injection
  • Figure 20. Product Picture of Compound Injection
  • Figure 21. Global Ceftriaxone Sodium Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
  • Figure 22. Global Ceftriaxone Sodium Sales Value Market Share by Application, 2024 & 2031
  • Figure 23. Global Ceftriaxone Sodium Sales Volume by Application (2020 VS 2024 VS 2031) & (MT)
  • Figure 24. Global Ceftriaxone Sodium Sales Volume Market Share by Application, 2024 & 2031
  • Figure 25. Global Ceftriaxone Sodium Price by Application (2020-2031) & (USD/Kg)
  • Figure 26. North America Ceftriaxone Sodium Sales Value (2020-2031) & (US$ Million)
  • Figure 27. North America Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
  • Figure 28. Europe Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 29. Europe Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
  • Figure 30. Asia Pacific Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 31. Asia Pacific Ceftriaxone Sodium Sales Value by Region (%), 2024 VS 2031
  • Figure 32. South America Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 33. South America Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
  • Figure 34. Middle East & Africa Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 35. Middle East & Africa Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
  • Figure 36. Key Countries/Regions Ceftriaxone Sodium Sales Value (%), (2020-2031)
  • Figure 37. Key Countries/Regions Ceftriaxone Sodium Sales Volume (%), (2020-2031)
  • Figure 38. United States Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 39. United States Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • Figure 40. United States Ceftriaxone Sodium Sales Value by Application (%), 2024 VS 2031
  • Figure 41. Europe Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 42. Europe Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • Figure 43. Europe Ceftriaxone Sodium Sales Value by Application (%), 2024 VS 2031
  • Figure 44. China Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 45. China Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • Figure 46. China Ceftriaxone Sodium Sales Value by Application (%), 2024 VS 2031
  • Figure 47. Japan Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 48. Japan Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • Figure 49. Japan Ceftriaxone Sodium Sales Value by Application (%), 2024 VS 2031
  • Figure 50. South Korea Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 51. South Korea Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • Figure 52. South Korea Ceftriaxone Sodium Sales Value by Application (%), 2024 VS 2031
  • Figure 53. Southeast Asia Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 54. Southeast Asia Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • Figure 55. Southeast Asia Ceftriaxone Sodium Sales Value by Application (%), 2024 VS 2031
  • Figure 56. India Ceftriaxone Sodium Sales Value, (2020-2031) & (US$ Million)
  • Figure 57. India Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • Figure 58. India Ceftriaxone Sodium Sales Value by Application (%), 2024 VS 2031
  • Figure 59. Ceftriaxone Sodium Industrial Chain
  • Figure 60. Ceftriaxone Sodium Manufacturing Cost Structure
  • Figure 61. Channels of Distribution (Direct Sales, and Distribution)
  • Figure 62. Bottom-up and Top-down Approaches for This Report
  • Figure 63. Data Triangulation
  • Figure 64. Key Executives Interviewed